Log in to search using one of your social media accounts:

 

Thalassemia Major: Transplantation or Transfusion and Chelation
Publication date: Available online 20 June 2017 Source:Hematology/Oncology and Stem Cell Therapy Author(s): Said Y. Mohamed Thalassemia is the most common monogenic hematologic disease that affects millions in the world and kills thousands of patients every year. Without transfusion or transplantation, patients with thalassemia major are expected to die within months of diagnosis. However, long-term transfusion and chelation therapy is highly challenging for many developing countries where the disease is prevalent, representing a major and unsustainable health burden. Stem cell transplantation is the only cure for thalass...
Source: Hematology Oncology and Stem Cell Therapy - November 10, 2017 Category: Cancer & Oncology Source Type: research

Aging and stem cell therapy: AMPK as an applicable pharmacological target for rejuvenation of aged stem cells and achieving higher efficacy in stem cell therapy
Publication date: Available online 19 October 2017 Source:Hematology/Oncology and Stem Cell Therapy Author(s): Mohammadhossein Khorraminejad-Shirazi, Mohammad Farahmandnia, Bahareh Kardeh, Alireza Estedlal, Sina Kardeh, Ahmad Monabati In recent years, tissue regeneration has become a promising field for developing stem cell-based transplantation therapies for human patients. Adult stem cells are affected by the same aging mechanisms that involve somatic cells. One of the mechanisms involved in cellular aging is hyperactivation of mechanistic target of rapamycin complex 1 (mTORC1) and disruption of 5′ adenosine monop...
Source: Hematology Oncology and Stem Cell Therapy - November 3, 2017 Category: Cancer & Oncology Source Type: research

CD209-336A/G promotor polymorphism and its clinical associations in sickle cell disease Egyptian Pediatric patients
Conclusion We found no significant difference between our population of Egyptian SCD cases and controls regarding CD209 A>G polymorphism. Infections occurred more frequently among the heterozygous genotype (AG) and homozygous genotype (GG) patients. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - October 31, 2017 Category: Cancer & Oncology Source Type: research

Evaluation of Weekly Paclitaxel plus Carboplatin Followed by Anthracycline Chemotherapy on the Neoadjuvant Treatment of Patients with Triple-Negative Breast Cancer
Conclusion The combination of neoadjuvant chemotherapy with wP + wCb before anthracycline chemotherapy can be tolerated by patients with triple-negative breast cancer. Complete pathologic response rates were comparable with those historically seen. Careful selection of patients is fundamental as this regimen is associated with a high incidence of hematologic toxicity. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - October 28, 2017 Category: Cancer & Oncology Source Type: research

CD209 -336A/G Promotor Polymorphism and its Clinical Associations in Sickle cell disease Egyptian Pediatric Patients
Conclusion We found no significant difference between our population of Egyptian SCD cases and controls regarding CD209 A>G polymorphism. Infections occurred more frequently among the heterozygous genotype (AG) and homozygous genotype (GG) patients. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - October 26, 2017 Category: Cancer & Oncology Source Type: research

Ageing and Stem cell therapy: AMPK as an applicable pharmacological target for Rejuvenation of Aged Stem Cells and achieving higher efficacy in stem cell therapy
Publication date: Available online 19 October 2017 Source:Hematology/Oncology and Stem Cell Therapy Author(s): Mohammadhossein Khorraminejad-Shirazi, Mohammad Farahmandnia, Bahareh Kardeh, Alireza Estedlal, Sina Kardeh, Ahmad Monabati In recent years, tissue regeneration has become a promising field for developing stem cell-based transplantation therapies for human patients. Adult stem cells are affected by the same aging mechanisms that involve somatic cells. One of the mechanisms involved in cellular aging is hyperactivation of mechanistic target of rapamycin complex 1 (mTORC1) and disruption of 5’ adenosine monop...
Source: Hematology Oncology and Stem Cell Therapy - October 19, 2017 Category: Cancer & Oncology Source Type: research

Successful Treatment of Pure Red Cell Aplasia with High-Dose Dexamethasone after ABO-Incompatible Allogeneic Hematopoietic Stem Cell Transplantation
Publication date: Available online 18 October 2017 Source:Hematology/Oncology and Stem Cell Therapy Author(s): Rosario Varela Gomez, Goretti Vázquez Vazquez, Victor Noriega Concepcion, Andrea Galego Garcia, Concepción Andón Saavedra The literature reports an incidence of Pure Red Cell Aplasia (PRCA) ranging from 6-30% of all cases of ABO-incompatible HSCT. Although most patients resolve spontaneously after withdrawal immunosuppression, some of them require more aggressive treatment to manage this condition. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - October 18, 2017 Category: Cancer & Oncology Source Type: research

DNMT3A (R882) Mutation Features and Prognostic Effect in Acute Myeloid Leukemia in Coexistent with NPM1 and FLT3 Mutations
Conclusion DNMT3A R882 mutation plays an important role in CN-AML patients’ prognosis and clinical outcomes in the presence and absence of NPM1 and FLT3 mutations. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - October 18, 2017 Category: Cancer & Oncology Source Type: research

Limited Role of Bone Marrow Biopsy for Detection of Marrow Involvement in Patients with Hodgkin Lymphoma from the Middle East and North Africa Region
Publication date: Available online 18 October 2017 Source:Hematology/Oncology and Stem Cell Therapy Author(s): Moussab Damlaj, Gamal Gmati, Ghulam Syed, Tabrez Pasha, Hend Salama, Osama Ali, Khadega A. Abuelgasim, Mohsen Al-Zahrani, Ahmad Al Askar, Ayman Alhejazi (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - October 18, 2017 Category: Cancer & Oncology Source Type: research

Double CD38 −/CD138− negative multiple myeloma
Publication date: Available online 18 October 2017 Source:Hematology/Oncology and Stem Cell Therapy Author(s): Vitaliy Mykytiv, Abrar Alwaheed, Nurul Asyikin Mohd Hashim (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - October 18, 2017 Category: Cancer & Oncology Source Type: research

Hereditary persistence of hemoglobin F is protective against red cell sickling. A case report and brief review
We describe a case of SCD, in which a patient with high HbF level presented at a very late age (27 years old). We presume the patient’s inherently elevated HbF levels were able to compensate for the hypoxic episodes associated with SCD. The onset of symptoms was delayed as a result of elevated HbF levels. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - October 16, 2017 Category: Cancer & Oncology Source Type: research

Anemia in Patient with Primary Hyperoxaluria and Bone Marrow Involvement by Oxalate Crystals
We present a rare case of anaemia secondary to bone marrow infiltration by oxalate crystals and renal failure in a patient diagnosed with primary hyperoxaluria. In our case, the anaemia was recovered after the double liver and kidney transplantation, the latter was performed on two occasions after the failure of the first graft. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - October 16, 2017 Category: Cancer & Oncology Source Type: research

Thrombo-hemorrhagic liability in children with congenital heart diseases
Conclusion Patients with CHD—both cyanotic and acyanotic—have variable degrees of increased liability for both thrombosis and hemorrhage that represents some sort of adaptation to preserve hemostasis and to protect these patients against the clinical presentation of both thrombosis and bleeding. This is to say that CHD patients have their own point of balance between thrombogenicity and bleeding liability. Wide-scale studies are needed to detect the normal levels of different thrombohemorrhagic parameters of these patients. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - August 27, 2017 Category: Cancer & Oncology Source Type: research

Presence of fluorescent in situ hybridization abnormalities is associated with plasma cell burden in light-chain amyloidosis
Conclusion We conclude that in AL, FISH abnormalities are associated with clonal burden. We found no impact of these markers on the type of organ involvement or 1-year survival. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - August 20, 2017 Category: Cancer & Oncology Source Type: research

Relevance of Bone Marrow Transplantation Nursing Training Program at King Faisal Specialist Hospital and Research Centre for National and Regional Nurses
Publication date: Available online 18 August 2017 Source:Hematology/Oncology and Stem Cell Therapy Author(s): Reguia Belkhedim (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - August 18, 2017 Category: Cancer & Oncology Source Type: research

Presence of FISH abnormalities is associated with plasma cell burden in light chain amyloidosis
Conclusion We conclude that in AL, FISH abnormalities are associated with clonal burden. We found no impact of these markers on the type of organ involvement or 1-year survival. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - August 17, 2017 Category: Cancer & Oncology Source Type: research

Impact of Vitamin D Deficiency on Increased Blood Eosinophil Counts
Conclusion Vitamin D deficiency was associated with higher blood eosinophil count. These results support the possible role of vitamin D in the eosinophil immune response. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - August 17, 2017 Category: Cancer & Oncology Source Type: research

Acute Promyelocytic Leukemia in a Patient with Chronic Lymphocytic Leukemia —A Case Report
Publication date: Available online 16 August 2017 Source:Hematology/Oncology and Stem Cell Therapy Author(s): Prajwal Boddu, Ellen Schlette, Beenu Thakral, Guillin Tang, Naveen Pemmaraju, Tapan Kadia, Alessandra Ferrajoli, Farhad Ravandi, William Wierda, Nitin Jain Chronic lymphocytic leukemia (CLL) is known to be associated rarely with myeloid malignancies such as acute myelogenous leukemia. In this article, we report an extremely rare occurrence of acute promyelocytic leukemia in a patient with CLL. A 71-year-old man first presented to our clinic with a diagnosis of CLL and worsening motor neuropathy symptoms. It was su...
Source: Hematology Oncology and Stem Cell Therapy - August 17, 2017 Category: Cancer & Oncology Source Type: research

Ruxolitinib for Secondary Hemophagocytic Lymphohistiocytosis: First Case Report
We describe a case of secondary HLH that did not respond favorably to conventional treatments. Serum inflammatory markers continued to rise significantly with clinical deterioration and worsening pancytopenia. The severe thrombocytopenia and neutropenia were deemed to have contributed to a spontaneous subdural hematoma and candidemia, respectively. Ruxolitinib, a Janus kinase (JAK) 1/2 inhibitor, was then utilized as a novel salvage therapy based on available in vivo murine data at the time. Following initiation, there was improvement seen in several disease markers, including serum ferritin, lactate dehydrogenase, fibrino...
Source: Hematology Oncology and Stem Cell Therapy - August 17, 2017 Category: Cancer & Oncology Source Type: research

Multimodality Therapy Improves Survival in Intramedullary Spinal Cord Metastasis of Lung Primary
Conclusion Lung cancer is the predominant cause of intramedullary involvement of the spinal cord. Overall prognosis is poor, although a multimodality approach was associated with improved survival. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - August 17, 2017 Category: Cancer & Oncology Source Type: research

Hematopoietic stem cell transplantation for sickle cell disease: The changing landscape
Publication date: Available online 15 June 2017 Source:Hematology/Oncology and Stem Cell Therapy Author(s): Adetola A. Kassim, Deva Sharma Allogeneic hematopoietic stem cell transplantation (HSCT) remains the only curative therapy for sickle cell disease (SCD); however, its use is limited by lack of suitable human leukocyte antigen (HLA)-matched donors and decreased application in older patients with significant morbidity. Myeloablative, HLA-identical sibling transplantation in children with SCD offers excellent long-term survival, with overall and event-free survival rates of 95% and 92%, respectively. However, the risk ...
Source: Hematology Oncology and Stem Cell Therapy - August 2, 2017 Category: Cancer & Oncology Source Type: research

Hematopoietic stem cell transplantation in Pakistan – country report
Publication date: Available online 22 July 2017 Source:Hematology/Oncology and Stem Cell Therapy Author(s): Parvez Ahmed, Tahir Sultan Shamsi, Salman Naseem Adil, Tariq Mahmood Satti, Qamar un Nisa Chaudhry, Syed Kamran Mahmood, Kamran Rashid, Saqib Ansari, Natasha Ali, Tariq Ghafoor (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - July 27, 2017 Category: Cancer & Oncology Source Type: research

Hematopoietic Stem Cell Transplantation in Pakistan - Country Report
Publication date: Available online 22 July 2017 Source:Hematology/Oncology and Stem Cell Therapy Author(s): Parvez Ahmed, Tahir Sultan Shamsi, Salman Naseem Adil, Tariq Mahmood Satti, Qamar un Nisa Chaudhry, Syed Kamran Mahmood, Kamran Rashid, Saqib Ansari, Natasha Ali, Tariq Ghafoor (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - July 23, 2017 Category: Cancer & Oncology Source Type: research

Current Concepts on Hematopoietic Stem Cell Transplantation Outcome Registries; Emphases on Resource Requirements for New Registries
Publication date: Available online 19 July 2017 Source:Hematology/Oncology and Stem Cell Therapy Author(s): Fazal Hussain, Naeem Chaudhri, Feras Alfraih, Mahmoud Aljurf There is tremendous variability in size, scope, and resource requirements for registries depending on the number of patients and participating sites. The outcome registries are organized systems to collect uniform data using an observational study methodology. Patient registries are used to determine specified outcomes for a population for predetermined scientific, clinical, or policy purposes. Historically, outcome registries established in the developmen...
Source: Hematology Oncology and Stem Cell Therapy - July 20, 2017 Category: Cancer & Oncology Source Type: research

Cost and Quality Issues in Establishing Hematopoietic Cell Transplant Program in Developing Countries
Publication date: Available online 14 July 2017 Source:Hematology/Oncology and Stem Cell Therapy Author(s): Shahrukh K. Hashmi, Alok Srivastava, Walid Rasheed, Salman Adil, Tong Wu, Madan Jagasia, Amr Nassar, William Y.K. Hwang, Amir Ali Hamidieh, Hildegard T. Greinix, Marcelo C. Pasquini, Jane F. Apperley, Mahmoud Aljurf The hematopoietic cell transplant (HCT) activity has grown significantly over the past two decades in both developing and developed countries. Many challenges arise in establishing new HCT programs in developing countries, due to scarcity of resources and manpower in expertise in HCT. While cost issues c...
Source: Hematology Oncology and Stem Cell Therapy - July 15, 2017 Category: Cancer & Oncology Source Type: research

Complications of hematopoietic stem cell transplantation: Bacterial infections
Publication date: Available online 3 July 2017 Source:Hematology/Oncology and Stem Cell Therapy Author(s): Ali S. Omrani, Reem S. Almaghrabi Bacterial infections remain a common complication of hematopoietic stem cell transplantation (HSCT), especially in the pre-engraftment phase. The risk of bacterial infections is mainly related to neutropenia, mucositis, and the presence of vascular lines. Most parts of the world have witnessed a shift in epidemiology toward Gram-negative bacteria; a large proportion of which are resistant to fluoroquinolones, extended-spectrum beta-lactams, carbapenems, and in some units even colisti...
Source: Hematology Oncology and Stem Cell Therapy - July 12, 2017 Category: Cancer & Oncology Source Type: research

Hematopoietic stem cell transplantation for acute myeloid leukemia: A review
Publication date: Available online 20 June 2017 Source:Hematology/Oncology and Stem Cell Therapy Author(s): Adetola A. Kassim, Bipib N. Savani Increasing numbers of patients are receiving allogeneic hematopoietic cell transplantation (HCT) for acute myeloid leukemia (AML). Scientific and clinical advances in supportive care, donor selection, and conditioning regimens have resulted in lower transplant-related mortality, extension of care to a wider population of patients, and improvements in survival. Recent era has witnessed an explosive information about the molecular pathophysiology of AML. By early identification of pa...
Source: Hematology Oncology and Stem Cell Therapy - July 11, 2017 Category: Cancer & Oncology Source Type: research

Hematopoietic Stem Cell Transplantation in Algeria
Publication date: Available online 11 July 2017 Source:Hematology/Oncology and Stem Cell Therapy Author(s): M.A. Bekadja, M. Brahimi, S. Osmani, N. Yafour, A. Krim, F. Serradj, S. Talhi, K. Amani, R. Bouhass Algeria is a country of 40.4 million inhabitants half of whom are younger than 30 years. In Algeria, healthcare insurance covers 90% of the population. Healthcare is free and it is supported by the Ministry of Health. Sixteen university hospitals exist in Algeria and only two (Algiers and Oran) practice bone marrow transplant. Hematologic malignancies in adults account for 10% (∼4,000 new cases/y) of the malignanc...
Source: Hematology Oncology and Stem Cell Therapy - July 11, 2017 Category: Cancer & Oncology Source Type: research

Plasmablastic Lymphoma Presenting as Exophytic Skin Lesions
Publication date: Available online 5 July 2017 Source:Hematology/Oncology and Stem Cell Therapy Author(s): Riad El Fakih, Muhamad Almahayni, Maamoun Alsermani (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - July 7, 2017 Category: Cancer & Oncology Source Type: research

Complications of Hematopoietic Stem Transplantation: Bacterial infections
Publication date: Available online 3 July 2017 Source:Hematology/Oncology and Stem Cell Therapy Author(s): Ali S. Omrani, Reem S. Almaghrabi Bacterial infections remain a common complication of hematopoietic stem cell transplantation (HSCT), especially in the pre-engraftment phase. The risk of bacterial infections is mainly related to neutropenia, mucositis, and the presence of vascular lines. Most parts of the world have witnessed a shift in epidemiology towards Gram-negative bacteria; a large proportion of which are resistant to fluoroquinolones, extended-spectrum beta-lactams, carbapenems, and in some units even colist...
Source: Hematology Oncology and Stem Cell Therapy - July 4, 2017 Category: Cancer & Oncology Source Type: research

Establishing an Autologous versus Allogeneic Hematopoietic Cell Transplant Program in Nations with Emerging Economies
The objective of the transplant procedure is to improve the survival and quality of life of patients. The regional difference that one notices in emerging countries about the higher number of allo-HCT compared with auto-HCT procedures performed is primarily based on suboptimal health-care network in treating various malignant disorders that are the primary indication for auto-stem cell transplantation. In this context, nonmalignant disorders such as bone marrow failure syndromes, inherited genetic disorders, and hemoglobinopathies have become the major indication for stem cell transplantation. Better understanding of these...
Source: Hematology Oncology and Stem Cell Therapy - July 4, 2017 Category: Cancer & Oncology Source Type: research

Practical Implementation – Essential Elements Resource Tool
In conclusion, new and developing stem cell transplantation programs should focus on quality and safety and step on the path towards full accreditation. The HSCT community must continue its efforts to offer education and training to support developing programs to attain accreditation. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - June 30, 2017 Category: Cancer & Oncology Source Type: research

Hematopoietic Stem Cell Transplantation in Qatar: One-Year Anniversary
Publication date: Available online 29 June 2017 Source:Hematology/Oncology and Stem Cell Therapy Author(s): Mohammad Bakr, Ibrahim Al-Hijji, Naziha Menasria, Zeyd Merenkov, Safaa Al-Azzawi, Ruba Taha, Amaal Gulied, Catherine Anne Gillespie, Said Dermime, Effie Liakopoulou, Alexander Knuth Hematopoietic stem cell transplantation (HSCT) offers potentially curative therapy for many hematologic and nonhematologic conditions. As a successful outcome of Qatar’s National Cancer Strategy, the HSCT program was started in the National Center for Cancer Care and Research (NCCCR) in October 2015. The HSCT program in NCCCR is th...
Source: Hematology Oncology and Stem Cell Therapy - June 30, 2017 Category: Cancer & Oncology Source Type: research

Current Indication for Hematopoietic Cell Transplantation in Adults
Publication date: Available online 30 June 2017 Source:Hematology/Oncology and Stem Cell Therapy Author(s): Shinichiro Okamoto With advances in transplantation technology and supportive care practices, hematopoietic cell transplantation (HCT) has become relatively safer and the applicability of HCT continues to expand. However, appropriate selection of transplant candidates remains challenging. Identifying adult patients who may benefit from HCT involves consideration of patient and disease factors, including overall health, prior therapies, age, comorbidity, and disease/disease risk. The eligibility of transplants should...
Source: Hematology Oncology and Stem Cell Therapy - June 30, 2017 Category: Cancer & Oncology Source Type: research

Nursing Challenges Caring for Bone Marrow Transplantation Patients with Graft Versus Host Disease
Publication date: Available online 28 June 2017 Source:Hematology/Oncology and Stem Cell Therapy Author(s): Joyce Neumann (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - June 29, 2017 Category: Cancer & Oncology Source Type: research

Kuwait Bone Marrow Transplantation Activities
Publication date: Available online 22 June 2017 Source:Hematology/Oncology and Stem Cell Therapy Author(s): Salem H Alshemmar, Reem Ameen Kuwait is located in the Arabian Gulf and has a population of 3.5 million. The stem cell transplantation program started in 2000. Autologous peripheral blood stem cell transplantation started first, as it was easier technically to establish. In 2011, the allogeneic program started with focus on acute leukemia and hemoglobinopathies. The success of both programs required teamwork and support of health planners. We are in the process of establishing a bone marrow donor registry. The issue...
Source: Hematology Oncology and Stem Cell Therapy - June 23, 2017 Category: Cancer & Oncology Source Type: research

Thalassemia Major: Transfusion and Chelation or Transplantation
Publication date: Available online 20 June 2017 Source:Hematology/Oncology and Stem Cell Therapy Author(s): Said Yousuf Mohamed Thalassemia is the most common monogenic hematologic disease that affects millions in the world and kills thousands of patients every year. Without transfusion or transplantation, patients with thalassemia major are expected to die within months of diagnosis. However, long-term transfusion and chelation therapy is highly challenging for many developing countries where the disease is prevalent, representing a major and unsustainable health burden. Stem cell transplantation is the only cure for tha...
Source: Hematology Oncology and Stem Cell Therapy - June 21, 2017 Category: Cancer & Oncology Source Type: research

Hematopoietic Cell Transplantation in Hematological Malignancies: Hematopoietic Cell Transplantation in Acute Myeloid Leukemia
Publication date: Available online 20 June 2017 Source:Hematology/Oncology and Stem Cell Therapy Author(s): Adetola Kassim, Bipin N. Savani Increasing numbers of patients are receiving allogeneic hematopoietic cell transplantation (HCT) for acute myeloid leukemia (AML). Scientific and clinical advances in supportive care, donor selection, and conditioning regimens have resulted in lower transplant-related mortality, extension of care to a wider population of patients, and improvements in survival. Recent era has witnessed an explosive information about the molecular pathophysiology of AML. By early identification of patie...
Source: Hematology Oncology and Stem Cell Therapy - June 21, 2017 Category: Cancer & Oncology Source Type: research

End of therapy minimal residual disease (MRD) measurement in children with ALL does not predict relapse
Publication date: Available online 17 June 2017 Source:Hematology/Oncology and Stem Cell Therapy Author(s): Tahani Hani Sarrawi, Ismael Zayyat, Fareed Barakat, Maha Rezeq, Salam Abu Jmaian, Faris Madanat (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - June 20, 2017 Category: Cancer & Oncology Source Type: research

Hematopoietic Stem Cell Transplantation in the Sultanate of Oman
Publication date: Available online 17 June 2017 Source:Hematology/Oncology and Stem Cell Therapy Author(s): Murtadha Al-Khabori, Mohammed Al-Huneini The Sultanate of Oman is one of the Arabian Gulf countries with a total population of 4,414,051 as of mid 2016, of whom 2,427,825 are Omanis. The gross national income per capita was 7327.7 RO (Omani rial; equivalent to US$19,033) in 2014. There are two hematopoietic stem cell transplantation (HSCT) centers in Oman: the Sultan Qaboos University Hospital (SQUH; allogeneic and autologous) and the Royal Hospital (RH; autologous). HSCT activity in Oman started in 1995 at the SQUH...
Source: Hematology Oncology and Stem Cell Therapy - June 20, 2017 Category: Cancer & Oncology Source Type: research

Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia in Adult Patients
Publication date: Available online 15 June 2017 Source:Hematology/Oncology and Stem Cell Therapy Author(s): Riad El Fakih, Syed Ahmed, Feras Alfraih, Amr Hanbali Acute lymphoblastic leukemia (ALL) consists of precursor B ALL or T ALL phenotypes. In the pediatric population, ALL patients enjoy an 80% long-term survival with the current pediatric chemotherapy protocols as compared with 50% long-term survival in the adult population. In adults, complete remission rates are similar to those of pediatric patients; however, long-term survival is much lower with the majority of deaths attributable to relapsed disease. Postremiss...
Source: Hematology Oncology and Stem Cell Therapy - June 16, 2017 Category: Cancer & Oncology Source Type: research

Comparison of Cyclophosphamide –Thalidomide–Dexamethasone to Bortezomib–Cyclophosphamide–Dexamethasone as Induction Therapy for Multiple Myeloma Patients in Brazil
Conclusion VCD afforded better responses than the CTD protocol, and improved patient condition before autologous HSCT. However, more studies are necessary including more patients and addressing various clinical conditions, besides the analysis of cost-effectiveness of these treatments. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - June 16, 2017 Category: Cancer & Oncology Source Type: research

Giant-Cell Tumor of Bone with Pathological Evidence of Blood Vessel Invasion
Publication date: Available online 15 June 2017 Source:Hematology/Oncology and Stem Cell Therapy Author(s): Shadi Khalil, Rachana Yendala, Nicholas D'Cunha, Fred Hardwicke, Mohamed Shanshal (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - June 16, 2017 Category: Cancer & Oncology Source Type: research

Hematological Parameters and Red Blood Cell Morphological Abnormality of Glucose-6-Phosphate Dehydrogenase Deficiency Co-Inherited With Thalassemia
Conclusion G-6-PD deficiency co-inherited with thalassemia in males was present in 10% of the participants, resulting in worsening of red blood cell pathology compared with inheritance of thalassemia alone. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - June 16, 2017 Category: Cancer & Oncology Source Type: research

Hematopoietic Stem Cell Transplantation for Sickle Cell Anemia: The Changing Landscape
Publication date: Available online 15 June 2017 Source:Hematology/Oncology and Stem Cell Therapy Author(s): Adetola A. Kassim, Deva Sharma Allogeneic hematopoietic stem cell transplantation (HSCT) remains the only curative therapy for sickle cell disease (SCD); however, its use is limited by lack of suitable human leukocyte antigen (HLA)-matched donors and decreased application in older patients with significant morbidity. Myeloablative, HLA-identical sibling transplantation in children with SCD offers excellent long-term survival, with overall and event-free survival rates of 95% and 92%, respectively. However, the risk ...
Source: Hematology Oncology and Stem Cell Therapy - June 16, 2017 Category: Cancer & Oncology Source Type: research

Study of Platelet Activation, Hypercoagulable State, and the Association with Pulmonary Hypertension in Children with β-Thalassemia
Conclusion A chronic hypercoagulable state and platelet activation is present in children with β-thalassemia. Splenectomy and transfusion infrequency are the main risk factors noted to be associated with such hypercoagulable state and platelet activation and consequently the PH among our thalassemic patients. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - June 16, 2017 Category: Cancer & Oncology Source Type: research

Treatment with Methotrexate, Rituximab, and Cytosine Arabinoside Followed by Autologous Stem Cell Transplantation in Primary Central Nervous System Lymphoma: A Single-center Experience
Conclusion R–MTX–ARA-C followed by autologous stem cell transplantation seems a promising strategy with high response rates in PCNSL. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - June 16, 2017 Category: Cancer & Oncology Source Type: research

Hematopoietic Cell Transplantation in Fanconi Anemia and Dyskeratosis Congenita: A Minireview
Publication date: Available online 15 June 2017 Source:Hematology/Oncology and Stem Cell Therapy Author(s): Mouhab Ayas Bone marrow failure syndrome is an epithet of bone marrow failure (all or single-cell lineage) that is attributable to an underlying genetic aberration usually with a constellation of somatic abnormalities. Multiple inheritance patterns have been described in these disorders; many are transmitted in an autosomal recessive pattern, which may consequently lead to a higher prevalence of such illnesses in homogeneous societies such as Saudi Arabia, where consanguineous marriages are not uncommon. At King Fai...
Source: Hematology Oncology and Stem Cell Therapy - June 16, 2017 Category: Cancer & Oncology Source Type: research

High Dose Chemotherapy and Autologous Stem Cell Transplantation in Relapsed or Refractory Hodgkin Lymphoma: Emerging Questions, Newer Agents, and Changing Paradigm
Publication date: Available online 13 June 2017 Source:Hematology/Oncology and Stem Cell Therapy Author(s): Saad Akhtar Primary treatment for adult and pediatric patients with Hodgkin lymphoma (HL) using current multiagent anthracycline-based chemotherapy with or without radiation therapy will cure approximately > 70% of the patients; > 95% for early stage with a favorable risk profile and 70–75% with advanced stage and high risk features. Managing refractory and relapsed disease, however, remains a challenge. High dose chemotherapy (HDC) and autologous stem cell transplantation (auto-SCT) can salvage ...
Source: Hematology Oncology and Stem Cell Therapy - June 15, 2017 Category: Cancer & Oncology Source Type: research

Emerging Concepts in Cytomegalovirus Infection Following Hematopoietic Stem Cell Transplantation
Publication date: Available online 14 June 2017 Source:Hematology/Oncology and Stem Cell Therapy Author(s): Jose F. Camargo, Krishna V. Komanduri Despite the refinements in molecular methods for the detection of cytomegalovirus (CMV) and the advent of highly effective preemptive strategies, CMV remains a leading cause of morbidity and mortality in hematopoietic cell transplant (HCT) recipients. CMV can cause tissue-invasive disease including pneumonia, hepatitis, colitis, retinitis, and encephalitis. Mortality in HCT recipients with CMV disease can be as high as 60%. CMV infection has been associated with increased risk o...
Source: Hematology Oncology and Stem Cell Therapy - June 15, 2017 Category: Cancer & Oncology Source Type: research